Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Non-Current Assets (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Non-Current Assets for 10 consecutive years, with $150000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 93.92% year-over-year to $150000.0, compared with a TTM value of $150000.0 through Dec 2025, down 93.92%, and an annual FY2025 reading of $150000.0, down 93.92% over the prior year.
  • Non-Current Assets was $150000.0 for Q4 2025 at VYNE Therapeutics, down from $375000.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $6.1 million in Q1 2021 and bottomed at $150000.0 in Q4 2025.
  • Average Non-Current Assets over 5 years is $2.7 million, with a median of $2.5 million recorded in 2024.
  • The sharpest move saw Non-Current Assets surged 51.65% in 2024, then tumbled 93.92% in 2025.
  • Year by year, Non-Current Assets stood at $3.9 million in 2021, then crashed by 35.67% to $2.5 million in 2022, then tumbled by 30.65% to $1.7 million in 2023, then soared by 43.32% to $2.5 million in 2024, then crashed by 93.92% to $150000.0 in 2025.
  • Business Quant data shows Non-Current Assets for VYNE at $150000.0 in Q4 2025, $375000.0 in Q2 2025, and $1.5 million in Q1 2025.